Miscellaneous

Update: Iceland's Decode Genetics freezes in credit winter

23.11.2009

Reykjavik - Decode Genetics, a pioneering Icelandic biotechnology company, has filed for bankruptcy. The firm has been experiencing serious financial trouble since autumn last year when it informed investors of insufficient funds to carry on trading without selling off various business arms. The firm was one of the first in the world to market disease risk DNA tests directly to the public, and had invested heavily in basic research to uncover the genetic origins of conditions such as breast and prostate cancer, heart disease, and diabetes. This produced a string of publications in renowned scientific publications, but never generated a profit.
The company began work in 1996 with the central idea that, because of the populations's relatively undisturbed immigration history over the past 100 years, the Icelandic population is a resource for high quality genetic data. To date, Decode Genetics has collected the genetic information of 140,000 Icelanders. Thousands of others have committed their genetic profile to Decode Genetics for testing.
Now Saga Investments, a venture capital group has agreed to buy Decode's core science operations.the Iceland-based subsidiary Islensk Erfdagreining, and its drug discovery and development programs. This agreement is subject to a number of contingencies, including a competitive bidding procedure and court approval in accordance with bankruptcy law. Islensk Erfdagreining conducts deCODE’s human genetics research, manages its population genetics resources and provides its personal genome scans, DNA-based risk assessment tests, and genomics services for contract customers. deCode made clear that neither data nor samples can ever be sold, besause they are not owned by the firm but by the individuals who gave their informed consent for defined reseach purposes.


Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/update-icelands-decode-genetics-freezes-in-credit-winter.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • FORMYCON9.74 EUR9.44%
  • CYTOS0.29 CHF3.57%
  • BAYER118.00 EUR3.42%

FLOP

  • MAGFORCE6.12 EUR-2.55%
  • SARTORIUS95.00 EUR-2.06%
  • ADDEX3.01 CHF-1.95%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.25 EUR48.7%
  • STRATEC BIOMEDICAL48.65 EUR25.2%

FLOP

  • BIOFRONTERA2.53 EUR-12.8%
  • ADDEX3.01 CHF-8.8%
  • CO.DON2.53 EUR-8.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.53 EUR141.0%
  • BB BIOTECH182.60 EUR64.6%

FLOP

  • CYTOS0.29 CHF-91.5%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.39 EUR-41.1%

No liability assumed, Date: 23.11.2014

Current issue

All issues